Diagnostics and treatment of chronic kidney disease in modern clinical guidelines: what do practitioners need to know?
Chronic kidney disease (CKD), widely prevalent in real-world clinical practice settings, is associated with an increased risk of cardiovascular and renal complications. Modern clinical guidelines on the management of CKD patients provide recommendations on the early diagnostics of renal functional a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2013-10-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/423 |
| _version_ | 1797857111027220480 |
|---|---|
| author | V. V. Skibitskyi A. V. Fendrikova |
| author_facet | V. V. Skibitskyi A. V. Fendrikova |
| author_sort | V. V. Skibitskyi |
| collection | DOAJ |
| description | Chronic kidney disease (CKD), widely prevalent in real-world clinical practice settings, is associated with an increased risk of cardiovascular and renal complications. Modern clinical guidelines on the management of CKD patients provide recommendations on the early diagnostics of renal functional and structural pathology, as well as on the adequate treatment which prevents or postpones the progression of these pathological changes. Currently, the assessment of glomerular filtration rate and albuminuria severity is considered obligatory in the CKD diagnostics. These criteria are reflected in the CKD classification, presented in the modern clinical guidelines. The presence of CKD requires the administration of effective treatment, including renin-angiotensin-aldosterone system (RAAS) blockers. At the same time, most CKD patients also require antihypertensive combination therapy, which includes RAAS blockers, diuretics, and/or calcium antagonists. The choice of antihypertensive agents is defined by the specific clinical situation. One of the effective calcium antagonists with proven nephroprotective activity is lercanidipine. The treatment of CKD patients should also include adequate glycemia control and lipid-lowering agents. |
| first_indexed | 2024-04-09T20:51:22Z |
| format | Article |
| id | doaj.art-c37de6536d6743d193ab1af67af478f0 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:51:22Z |
| publishDate | 2013-10-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-c37de6536d6743d193ab1af67af478f02023-03-29T21:23:20Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202013-10-0105667210.15829/1560-4071-2013-5-66-72423Diagnostics and treatment of chronic kidney disease in modern clinical guidelines: what do practitioners need to know?V. V. Skibitskyi0A. V. Fendrikova1Kuban State Medical University, Krasnodar, RussiaKuban State Medical University, Krasnodar, RussiaChronic kidney disease (CKD), widely prevalent in real-world clinical practice settings, is associated with an increased risk of cardiovascular and renal complications. Modern clinical guidelines on the management of CKD patients provide recommendations on the early diagnostics of renal functional and structural pathology, as well as on the adequate treatment which prevents or postpones the progression of these pathological changes. Currently, the assessment of glomerular filtration rate and albuminuria severity is considered obligatory in the CKD diagnostics. These criteria are reflected in the CKD classification, presented in the modern clinical guidelines. The presence of CKD requires the administration of effective treatment, including renin-angiotensin-aldosterone system (RAAS) blockers. At the same time, most CKD patients also require antihypertensive combination therapy, which includes RAAS blockers, diuretics, and/or calcium antagonists. The choice of antihypertensive agents is defined by the specific clinical situation. One of the effective calcium antagonists with proven nephroprotective activity is lercanidipine. The treatment of CKD patients should also include adequate glycemia control and lipid-lowering agents.https://russjcardiol.elpub.ru/jour/article/view/423chronic kidney diseaserenal functionalbuminuria |
| spellingShingle | V. V. Skibitskyi A. V. Fendrikova Diagnostics and treatment of chronic kidney disease in modern clinical guidelines: what do practitioners need to know? Российский кардиологический журнал chronic kidney disease renal function albuminuria |
| title | Diagnostics and treatment of chronic kidney disease in modern clinical guidelines: what do practitioners need to know? |
| title_full | Diagnostics and treatment of chronic kidney disease in modern clinical guidelines: what do practitioners need to know? |
| title_fullStr | Diagnostics and treatment of chronic kidney disease in modern clinical guidelines: what do practitioners need to know? |
| title_full_unstemmed | Diagnostics and treatment of chronic kidney disease in modern clinical guidelines: what do practitioners need to know? |
| title_short | Diagnostics and treatment of chronic kidney disease in modern clinical guidelines: what do practitioners need to know? |
| title_sort | diagnostics and treatment of chronic kidney disease in modern clinical guidelines what do practitioners need to know |
| topic | chronic kidney disease renal function albuminuria |
| url | https://russjcardiol.elpub.ru/jour/article/view/423 |
| work_keys_str_mv | AT vvskibitskyi diagnosticsandtreatmentofchronickidneydiseaseinmodernclinicalguidelineswhatdopractitionersneedtoknow AT avfendrikova diagnosticsandtreatmentofchronickidneydiseaseinmodernclinicalguidelineswhatdopractitionersneedtoknow |